ARQ 501

DRUG6 trials

Sponsors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Conditions

Advanced Solid TumorsCancerCarcinomaCarcinoma, Squamous CellHead and Neck Neoplasms

Phase 1

ARQ 501 in Subjects With Cancer

CompletedNCT00075933

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Cancer

Start: 2003-09-30End: 2007-01-31Target: 80Updated: 2009-04-28

ARQ 501 in Combination With Docetaxel in Patients With Cancer

CompletedNCT00099190

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Carcinoma

Start: 2004-12-31End: 2006-11-30Target: 50Updated: 2009-04-28

An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors

CompletedNCT00524524

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Advanced Solid Tumors

Start: 2007-08-31End: 2008-08-31Updated: 2011-10-19

An Extension Study for Patients Previously Treated With ARQ 501

CompletedNCT00622063

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Cancer

Start: 2006-12-31Updated: 2013-02-28

Phase 2

Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma

CompletedNCT00310518

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Cancer

Start: 2006-02-28End: 2007-07-31Target: 30Updated: 2009-04-29

A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck

CompletedNCT00358930

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Carcinoma, Squamous Cell, Head and Neck Neoplasms

Start: 2006-07-31End: 2007-08-31Target: 60Updated: 2009-04-28